CSI Market
Sign In | Register

Vistagen Therapeutics Inc (VTGN) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access VTGN Annual Cash Flow →
Examining cash flow movements between Vistagen Therapeutics Inc and Jun 30 2025 reveals how Jun 30 2026 allocates cash as operating conditions evolve.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
3 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-13.03
Depreciation & amortization0.05
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.99
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Acquired In Process Research And Development-
Amortization Of Imputed Discount On Non Interest Bearing Notes-
Amortization Of Discounts On775 And10 Convertible Notes-
Amortization Of Discounts On Platinum Notes-
Amortization Of Discounts On August2010 Short Term Notes-
Change In Put And Note Term Extension Option And Warrant Liabilities-
Expense Related To Modification Of Warrants-
Fair Value Of Common Stock Granted For Services Following Merger-
Fair Value Of Warrants Granted For Services Following Merger-
Loss Gain On Currency Fluctuation-
Fair Value Of Additional Warrants Granted Under Discounted Warrant Exercise Program-
Change In Warrant Liability-
Expense Related To Modification Of Warrants Exchange Of Warrants For Series C Preferred And Common Stock-
Fair Value Of Common Stock Granted For Services-
Fair Value Of Series B Preferred Stock Granted For Services-
Modification Of Warrants-
Loss On Early Extinguishment Of Debt-
Amortization Of Fair Value Of Common Stock Issued For Services-
Operating Lease Right Of Use Asset Amortization Expense0.40
Expense Related To Asset Acquisition-
Increase Decrease In Contract With Customer Liability-0.75
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities-0.05
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets1.06
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-3.73
Discontinued operations0.00
Net Cash flow from Operating Activities-14.71
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities5.60
Payments to Acquire Available-for-sale Securities, Debt-5.60
Real Estate Investments0.00
Dividends Payable Current And Noncurrent-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-0.10
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Increase (Decrease) in Deposits Outstanding0.00
Other financing activities net0.00
Other net0.00
Net Proceeds From Issuance Of Platinum Notes And Warrants-
Net Proceeds From Issuance Of20082010 Notes And Warrants-
Net Proceeds From Issuance Of20062007 Notes And Warrants-
Proceeds From Issuance Of7 Notes Payable-
Net Proceeds From Issuance Of August2010 Short Term Notes And Warrants-
Proceeds From Exercise Of Warrants Under Discounted Warrant Exercise Program-
Proceeds From Exercise Of Modified Warrants Mayjune2012 And Under Discounted Warrant Exercise Program-
Proceeds From Issuance Of7 Note Payable To Founding Stockholder-
Proceeds From Exercise Of Modified Warrants-
Net Proceeds From Issuance Of Series B Preferred Units-
Proceeds From Sale Of Warrants-
Proceeds From Issuance Of Common Stock Warrants And Option Exercises-
Proceeds From Warrant Exercises Net-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.91
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-14.71
Total Cash Flow-13.80
4 historic quarters locked

Sign in to unlock the full Vistagen Therapeutics Inc cash flow history.

Sign In Create Free Account

About Vistagen Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-057116

Figures are derived from filed reports and may be restated. Historical data is subject to revision.